Drugs / Dupilumab
Regulatory milestones approvals, filings & regulatory actions · 21 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (19) | US (FDA) | DUPIXENT | — | 2018-04-10 – 2026-04-22 | fda.gov ↗ |
| Approved | EU (EMA) | Dupixent | — | 2017-09-26 | europa.eu ↗ |
| Approved | US (FDA) | DUPIXENT | — | 2017-03-28 | fda.gov ↗ |
Trials 174 · started per year
today
US approved 2017
EU approved 2017
1
1
3
4
5
6
8
4
6
14
10
24
20
13
20
18
9
5
2010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT06637306 | Mar 2025 → Mar 2027 expected | triple-negative breast carcinoma | Rima Patel | Recruiting | No outcome recorded |
| Phase 0 | NCT05649098 | Jun 2023 → Jun 2031 expected | skin disorder | Northwestern University | Recruiting | No outcome recorded |
| Phase 0 | NCT05372003 | Aug 2022 → Feb 2024 | atopic eczema | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT04943744 | May 2021 → May 2024 | eosinophil disorder, food allergy | Stanford University | Terminated | No outcome recorded |
| Phase 0 | NCT03675022 | Aug 2018 → Jul 2022 | chronic rhinosinusitis, obstructive sleep apnea syndrome | Brigham and Women's Hospital | Terminated | No outcome recorded |
| Phase 113 trials | ||||||
| Phase 1 | NCT07646548 | Jun → Sep 2026 expected | — | Sanofi | Recruiting | No outcome recorded |
| Phase 1 | NCT05976386 | Jun → Sep 2021 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT03112577 | Jun 2017 → Mar 2019 | allergic asthma | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03050151 | Feb → Nov 2017 | atopic IgE-mediated allergic disorder, atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02647086 | Dec 2015 → Jul 2016 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05976373 | Jan → Mar 2015 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT05976360 | Nov 2014 → Jan 2015 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01537653 | Mar → Oct 2012 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01537640 | Feb → Jul 2012 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01484600 | Dec 2011 → Feb 2012 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01385657 | Jul 2011 → Mar 2012 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01259323 | Dec 2010 → Jul 2012 | dermatitis | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01015027 | Oct 2009 → Jul 2010 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07277322 | Jun 2026 → Dec 2028 expected | metastasis from malignant tumor of colon | Dan Feng | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06088771 | Mar 2024 → Apr 2026 overdue | non-small cell lung carcinoma | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05013450 | Sep 2021 → Sep 2025 overdue | non-small cell lung carcinoma | Thomas Marron | Active not recruiting | No outcome recorded |
| Phase 243 trials | ||||||
| Phase 2 | NCT07330934 | Dec 2025 → Jun 2027 expected | atopic eczema | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07091175 | Nov 2025 → Feb 2028 expected | nephrotic syndrome | National University Hospital, Singapore | Recruiting | No outcome recorded |
| Phase 2 | NCT06477653 | Feb 2025 → Dec 2026 expected | hypereosinophilic syndrome | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 2 | NCT05866562 | Jul 2024 → Aug 2028 expected | alopecia areata | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 2 | NCT05031455 | Mar 2024 → Apr 2026 | aspirin-induced respiratory disease | Scripps Clinic | Completed | No outcome recorded |
| Phase 2 | NCT05967884 | Aug 2023 → Aug 2024 | breast cancer | Ottawa Hospital Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT05575037 | Aug 2023 → Apr 2026 overdue | aspirin-induced respiratory disease, asthma, nasal polyps, and aspirin intolerance, nasal cavity polyp | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05831176 | May 2023 → Feb 2026 overdue | eosinophilic gastritis | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05551793 | Apr 2023 → Nov 2027 expected | alopecia areata | Emma Guttman | Recruiting | No outcome recorded |
| Phase 2 | NCT05720325 | Mar 2023 → Nov 2026 expected | allergic asthma | The University of Texas Health Science Center at San Antonio | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05128383 | Jan 2023 → May 2025 | keloid | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT05731128 | Jan 2023 → May 2026 overdue | ulcerative colitis | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05347771 | May 2022 → Dec 2026 expected | asthma | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04148352 | Oct 2021 → Dec 2024 | food allergy | Andrew J Long, PharmD | Terminated | No outcome recorded |
| Phase 2 | NCT04920916 | May 2021 → Apr 2023 | COVID-19 | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT04600362 | Mar 2021 → Sep 2025 overdue | — | Technical University of Munich | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04502966 | Nov 2020 → Feb 2025 | seasonal allergic rhinitis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04362501 | Oct 2020 → Sep 2025 | chronic rhinosinusitis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT04442269 | Sep 2020 → Jul 2023 | allergic bronchopulmonary aspergillosis | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04256759 | Sep 2020 → Sep 2024 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT04200755 | May 2020 → Nov 2023 | localized scleroderma | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT04296864 | Feb 2020 → Jan 2025 | atopic keratoconjunctivitis | Andover Eye Associates | Unknown | No outcome recorded |
| Phase 2 | NCT03679676 | Feb 2020 → Apr 2025 | food allergy, insect Stings, hypersensitivity to | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT03886493 | Aug 2019 → Oct 2020 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 2 | NCT03861455 | Jul 2019 → Nov 2023 | — | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 2 | NCT03793608 | Mar 2019 → Feb 2021 | food allergy | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03736967 | Nov 2018 → Mar 2020 | atopic eczema | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT03682770 | Oct 2018 → Oct 2020 | food allergy | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03595488 | Sep 2018 → Dec 2019 | aspirin-induced respiratory disease | Rochester General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03558997 | Jun 2018 → May 2019 | allergic rhinitis | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03387852 | Mar 2018 → Mar 2019 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT03359356 | Jan 2018 → Jan 2020 | alopecia areata | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT02573233 | Jan 2016 → Jan 2018 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT02379052 | May 2015 → Feb 2017 | eosinophilic esophagitis | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02407756 | Mar 2015 → Mar 2016 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02210780 | Aug 2014 → Sep 2015 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01979016 | Dec 2013 → Dec 2014 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01920893 | Aug 2013 → Nov 2014 | nasal cavity polyp | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01854047 | Jun 2013 → Nov 2014 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01859988 | May 2013 → May 2014 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01639040 | Jul → Dec 2012 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01548404 | Apr 2012 → Mar 2013 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01312961 | Mar 2011 → Oct 2012 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT05535738 | Nov 2022 → Jan 2027 expected | allergic contact dermatitis | Wei-Che Ko | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04206553 | Oct 2020 → Jul 2024 | bullous pemphigoid | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT04244006 | Jul 2020 → Jun 2024 | Netherton syndrome | University Hospital, Toulouse | Unknown | No outcome recorded |
| Phase 2/3 | NCT03346434 | Nov 2017 → Jul 2021 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 347 trials | ||||||
| Phase 3 | NCT07309614 | Jan 2026 → Jan 2029 expected | asthma | University of Sherbrooke | Recruiting | No outcome recorded |
| Phase 3 | NCT07112378 | Nov 2025 → Jun 2028 expected | eosinophilic esophagitis | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06687967 | Nov 2024 → Jun 2026 overdue | neurodermatitis | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06687980 | Nov 2024 → Jun 2026 overdue | neurodermatitis | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06461897 | Aug 2024 → Jul 2030 expected | atopic eczema | AbbVie | Recruiting | No outcome recorded |
| Phase 3 | NCT06461949 | Jul 2024 | asthma, chronic rhinosinusitis, nasal cavity polyp | National Institute on Deafness and Other Communication Disorders (NIDCD) | Withdrawn | No outcome recorded |
| Phase 3 | NCT06389136 | Jun 2024 → Aug 2026 overdue | atopic eczema | AbbVie | Recruiting | No outcome recorded |
| Phase 3 | NCT06293053 | May 2024 → Oct 2027 expected | prurigo nodularis | Sanofi | Recruiting | No outcome recorded |
| Phase 3 | NCT06191315 | Jan 2024 → Dec 2028 expected | asthma | Sanofi | Recruiting | No outcome recorded |
| Phase 3 | NCT05545072 | Oct 2023 → Jul 2024 | chronic rhinosinusitis | Emory University | Terminated | No outcome recorded |
| Phase 3 | NCT05878093 | May 2023 → Sep 2024 | chronic rhinosinusitis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT05601882 | Nov 2022 → Mar 2024 | atopic eczema | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT05526521 | Aug 2022 → Nov 2024 | chronic idiopathic urticaria | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT05263206 | Feb 2022 → Jun 2027 expected | — | Sanofi | Recruiting | No outcome recorded |
| Phase 3 | NCT04417894 | Apr 2021 → Aug 2022 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04678882 | Jan → Dec 2021 | atopic eczema | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT04681729 | Dec 2020 → Feb 2023 | cold urticaria | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT04678856 | Dec 2020 → Nov 2023 | chronic rhinosinusitis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT04684524 | Dec 2020 → Dec 2024 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT04394351 | Sep 2020 → Jun 2022 | eosinophilic esophagitis | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04456673 | Jul 2020 → Feb 2024 | chronic obstructive pulmonary disease | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT04345367 | Jun 2020 → Jul 2021 | atopic eczema | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT04202679 | Jan 2020 → Aug 2021 | neurodermatitis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT04183335 | Dec 2019 → Nov 2021 | neurodermatitis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT04180488 | Dec 2019 → Aug 2024 | chronic idiopathic urticaria | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03930732 | Apr 2019 → Feb 2023 | chronic obstructive pulmonary disease | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03738397 | Feb 2019 → Aug 2020 | atopic eczema | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03782532 | Jan 2019 → May 2022 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03912259 | Dec 2018 → Feb 2020 | atopic eczema | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03633617 | Sep 2018 → Sep 2021 | eosinophilic esophagitis | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03620747 | Aug 2018 → Feb 2022 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03560466 | Jun 2018 → Apr 2025 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03345914 | Nov 2017 → Jun 2019 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02948959 | Apr 2017 → Aug 2020 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03054428 | Mar 2017 → Apr 2018 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02912468 | Dec 2016 → Jul 2018 | chronic rhinosinusitis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02898454 | Nov 2016 → Aug 2018 | chronic rhinosinusitis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02755649 | Jan 2016 → Jan 2017 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02528214 | Oct 2015 → Sep 2017 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02612454 | Oct 2015 → Oct 2026 expected | atopic eczema | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02414854 | Apr 2015 → Jul 2017 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02395133 | Mar 2015 → Jul 2016 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02277769 | Nov 2014 → Oct 2015 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02277743 | Oct 2014 → Nov 2015 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02260986 | Sep 2014 → Aug 2015 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02134028 | Aug 2014 → Oct 2019 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01949311 | Oct 2013 → Jun 2022 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 453 trials | ||||||
| Phase 4 | NCT07352566 | Aug 2026 → Jun 2030 expected | atopic eczema, psoriasis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07587658 | Jun 2026 → Jul 2028 expected | chronic obstructive pulmonary disease | Regeneron Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07187089 | Nov 2025 → Dec 2027 | atopic eczema | Regeneron Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 4 | NCT07053423 | Sep 2025 → Dec 2028 expected | chronic obstructive pulmonary disease | Sanofi | Recruiting | No outcome recorded |
| Phase 4 | NCT06818019 | Apr 2025 → Dec 2027 expected | asthma | University Hospital, Toulouse | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06665971 | Nov 2024 → Sep 2026 expected | eosinophilic esophagitis | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 4 | NCT06572228 | Aug 2024 → Apr 2027 expected | asthma | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05042258 | Aug 2024 → Jun 2027 expected | atopic eczema, sleep disorder | Northwestern University | Recruiting | No outcome recorded |
| Phase 4 | NCT06188871 | Jun 2024 → Jun 2026 | chronic rhinosinusitis | University of Rochester | Withdrawn | No outcome recorded |
| Phase 4 | NCT06352073 | May 2024 → Apr 2026 overdue | eosinophilic esophagitis | University of North Carolina, Chapel Hill | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06116526 | Apr 2024 → Apr 2027 expected | atopic eczema | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 4 | NCT05983068 | Feb 2024 → Apr 2027 expected | atopic eczema | Sanofi | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06101095 | Nov 2023 → Nov 2025 overdue | eosinophilic esophagitis | Sanofi | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06012448 | Oct 2023 → Jan 2025 | hypersensitivity reaction disease | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT06366932 | Sep 2023 → Sep 2025 | atopic eczema | Instituto de Investigación Hospital Universitario La Paz | Unknown | No outcome recorded |
| Phase 4 | NCT06004986 | Aug 2023 → Oct 2025 overdue | atopic eczema | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 4 | NCT05964465 | Aug 2023 → Jan 2025 | chronic rhinosinusitis | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 4 | NCT05642208 | Mar 2023 → Sep 2026 expected | atopic eczema | Nantes University Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05680298 | Feb → Dec 2023 | atopic eczema | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT05858619 | Feb 2023 → Feb 2028 expected | atopic eczema | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 4 | NCT05268107 | Jan 2023 → Dec 2026 expected | atopic eczema | University of Michigan | Recruiting | No outcome recorded |
| Phase 4 | NCT05590585 | Jan 2023 → Nov 2024 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT05624112 | Nov 2022 → Jan 2024 | atopic eczema | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT05436535 | Nov 2022 → Apr 2025 | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT05094570 | Sep 2022 → Jun 2026 overdue | nasal cavity polyp, staphylococcus aureus infection | University of Virginia | Recruiting | No outcome recorded |
| Phase 4 | NCT05247866 | Jun 2022 → Jan 2025 | eosinophilic esophagitis | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 4 | NCT05285839 | Apr 2022 → Dec 2024 overdue | atopic eczema | Psoriasis Treatment Center of Central New Jersey | Recruiting | No outcome recorded |
| Phase 4 | NCT05265234 | Mar 2022 → Mar 2023 | atopic eczema | OptiSkin Medical | Unknown | No outcome recorded |
| Phase 4 | NCT05036733 | Feb 2022 → Jun 2023 | asthma | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT05097287 | Dec 2021 → Mar 2027 expected | asthma | Sanofi | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04895423 | Nov 2021 → Jul 2023 | atopic eczema | National Medical Research Center for Children's Health, Russian Federation | Unknown | No outcome recorded |
| Phase 4 | NCT05049122 | Oct 2021 → Dec 2022 | chronic rhinosinusitis | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT06750471 | Oct 2021 → Dec 2025 overdue | chronic rhinosinusitis, nasal cavity polyp | Madigan Army Medical Center | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04998604 | Sep 2021 → Oct 2024 | asthma, chronic rhinosinusitis | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT03694158 | Sep 2021 → Jan 2027 expected | asthma | Boston Children's Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04869436 | Jul 2021 → Sep 2025 overdue | chronic rhinosinusitis, olfactory nerve disorder | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Recruiting | No outcome recorded |
| Phase 4 | NCT04988022 | May 2021 → Mar 2025 | keloid | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT04596189 | May 2021 → Apr 2024 | chronic rhinosinusitis | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 4 | NCT04823130 | Apr 2021 → Jun 2022 | atopic eczema | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT04996485 | Mar 2021 → Mar 2023 | inherited ichthyosis | National Medical Research Center for Children's Health, Russian Federation | Unknown | No outcome recorded |
| Phase 4 | NCT04718870 | Feb 2021 → Sep 2022 | atopic eczema | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT04520308 | Sep 2020 → Feb 2021 | atopic eczema | Eric Simpson | Unknown | No outcome recorded |
| Phase 4 | NCT04358224 | Sep 2020 → Nov 2022 | atopic eczema | Jonathan A. Bernstein, MD | Completed | No outcome recorded |
| Phase 4 | NCT04502862 | Aug 2020 → Oct 2023 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT04447417 | Jul 2020 → Jun 2021 | atopic eczema | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT04203797 | Jul 2020 → Jul 2023 | asthma | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT04400318 | Jun 2020 → Jun 2023 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT04442256 | Jun 2020 → Dec 2022 | aspirin-induced respiratory disease | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT03935971 | Dec 2019 → Dec 2024 overdue | allergic contact dermatitis | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04033367 | Aug 2019 → Oct 2021 | atopic eczema | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT03667014 | Nov 2018 → Dec 2022 | atopic eczema | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT03293030 | Oct 2018 → Feb 2023 | atopic eczema | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT03389893 | Jul 2018 → Apr 2020 | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06743581 | Feb 2025 → Feb 2027 expected | non-small cell lung carcinoma | University of Montreal Hospital Centre (CHUM) | Not yet recruiting | No outcome recorded |
| — | NCT06501807 | Jul 2024 → Sep 2034 expected | chronic rhinosinusitis, nasal cavity polyp | University Hospital, Lille | Recruiting | No outcome recorded |
| — | NCT03983460 | Mar 2020 → Jun 2021 | atopic eczema | Association pour la Recherche Clinique et Immunologique | Unknown | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT06631677 | — | food allergy | Regeneron Pharmaceuticals | Available | No outcome recorded |
| — | NCT03020810 | — | asthma | Sally E. Wenzel MD | Approved for marketing | No outcome recorded |
| — | NCT05906706 | — | bullous pemphigoid | Regeneron Pharmaceuticals | Approved for marketing | No outcome recorded |
Also used as a comparator or background therapy in 37 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07358234 Comparator | Feb 2026 → Dec 2027 expected | eosinophilic esophagitis | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT07334496 Comparator | Mar → Jul 2026 overdue | — | Gan & Lee Pharmaceuticals. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07411755 Comparator | Mar → Sep 2026 expected | atopic eczema | Jiangsu Genscend Biopharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT07358156 Comparator | Feb → Nov 2026 expected | atopic eczema | Chong Kun Dang Pharmaceutical | Recruiting | No outcome recorded |
| Phase 1 | NCT07027527 Comparator | Jun 2025 → Dec 2026 expected | atopic eczema | Apogee Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06614907 Comparator | Aug → Nov 2024 | atopic eczema | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06369467 Background | May 2024 → Aug 2027 expected | food allergy | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06193434 Comparator | Jan 2024 → Aug 2025 | atopic eczema | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT07399067 Comparator | Feb 2026 → Mar 2027 expected | atopic eczema | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06881251 Comparator | Feb 2025 → Mar 2026 | atopic eczema | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT06705387 Comparator | Dec 2024 → Sep 2026 expected | eosinophilic esophagitis | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2 | NCT06226610 Comparator | Nov 2024 → Jan 2026 overdue | — | Akron Children's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05470114 Comparator | May 2022 → Jun 2023 | atopic eczema | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT03678545 Comparator | May 2021 → Mar 2024 | eosinophilic gastritis | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 2 | NCT04791319 Comparator | May 2021 → Feb 2022 | atopic eczema | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT04430179 Comparator | Dec 2020 → Jul 2025 overdue | chronic rhinosinusitis | University of South Florida | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04512339 Comparator | Aug 2020 → Aug 2022 | hand dermatosis | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 2 | NCT03749148 Comparator | Dec 2018 → Feb 2023 | cholinergic urticaria | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 2 | NCT03749135 Comparator | Nov 2018 → Jul 2021 | angioedema, chronic idiopathic urticaria | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07386743 Comparator | Feb 2026 → Apr 2027 expected | atopic eczema | Jiangsu Genscend Biopharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06868212 Comparator | Jul 2025 → Feb 2027 expected | chronic idiopathic urticaria | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06884891 Comparator | Apr 2025 → May 2027 expected | atopic eczema | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03884842 Comparator | Jul 2019 → Oct 2022 | asthma | McMaster University | Completed | No outcome recorded |
| Phase 3 | NCT03720470 Comparator | Oct 2018 → Dec 2019 | atopic eczema | Pfizer | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT06824649 Comparator | Jun 2026 → Feb 2030 expected | chronic rhinosinusitis, nasal cavity polyp | Medical University of South Carolina | Recruiting | No outcome recorded |
| Phase 4 | NCT07187583 Comparator | Jun 2025 → Mar 2028 expected | chronic rhinosinusitis | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
| Phase 4 | NCT07268313 Comparator | Apr 2025 → Jun 2027 expected | nasal cavity polyp | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
| Phase 4 | NCT06465732 Background | Jan → Nov 2025 overdue | atopic eczema | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06556264 Comparator | Aug 2024 → Jan 2025 overdue | asthma, chronic rhinosinusitis | Dr. Andrew Thamboo, MD | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06385236 Comparator | Feb 2024 → Jun 2027 expected | asthma | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 4 | NCT05942222 Comparator | Apr 2023 → Apr 2026 overdue | asthma, chronic rhinosinusitis, eosinophil disorder | Rigshospitalet, Denmark | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04743791 Comparator | Oct 2022 → Jul 2026 overdue | asthma | Sally E. Wenzel MD | Recruiting | No outcome recorded |
| Phase 4 | NCT04380038 Comparator | May 2022 → Jun 2026 overdue | asthma | University of Virginia | Recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05834413 Background | May 2023 → Jun 2027 expected | lung cancer | Shanghai University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT06509243 Comparator | Feb 2023 → Mar 2024 | atopic eczema | Medical University of Silesia | Completed | No outcome recorded |
| — | NCT04878770 Comparator | Aug 2021 → Jan 2024 | atopic eczema | Erasmus Medical Center | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04776694 Background | — | type II hypersensitivity reaction disease | Regeneron Pharmaceuticals | Approved for marketing | No outcome recorded |
Press releases naming this drug 234 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-05 | Regeneron Pharmaceuticals | Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial regeneron.com ↗ |
| 2026-04-22 | Sanofi | Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria sanofi.com ↗ |
| 2026-04-22 | Regeneron Pharmaceuticals | Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU) regeneron.com ↗ |
| 2026-04-13 | Sanofi | Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria sanofi.com ↗ |
| 2026-04-13 | Regeneron Pharmaceuticals | Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) regeneron.com ↗ |
| 2026-03-24 | Sanofi | Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid sanofi.com ↗ |
| 2026-03-24 | Regeneron Pharmaceuticals | Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP) regeneron.com ↗ |
| 2026-02-27 | Sanofi | Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment sanofi.com ↗ |
| 2026-02-27 | Regeneron Pharmaceuticals | Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment regeneron.com ↗ |
| 2026-02-24 | Sanofi | Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis sanofi.com ↗ |
| 2026-02-24 | Regeneron Pharmaceuticals | Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS) regeneron.com ↗ |
| 2025-12-23 | Sanofi | Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma sanofi.com ↗ |
| Show all 234 releases opens the full record — a long page | ||
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 212 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dupilumab | “Patients with moderate to severe atopic dermatitis refractory to topical medication, who also have previous experience with cyclosporine and an unsatisfactory response, or in...” NCT06366932 ↗198“Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Moderate-to-Severe Asthma, Type 2 Inflammation, and Nocturnal Awakenings: The MORPHEO Randomized Controlled Trial.” PMID 42370853 ↗ Jun 2026 “ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.” NCT05834413 ↗ “Dupilumab is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors” PMID 32348036 ↗ Apr 2020 “Dupilumab is a fully human monoclonal antibody that blocks the receptor component for IL-4 and IL-13, which are key drivers of type 2 inflammation.” NCT05031455 ↗ “Three biologic medications have been FDA approved and available for the treatment of CRSwNP: dupilumab, omalizumab, and mepolizumab.” NCT06824649 ↗ “the effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic inflammation” NCT04943744 ↗ “receiving mepolizumab (100 mg) or dupilumab (300 mg) every 4 weeks” NCT07187583 ↗ “U.S. commercial dupilumab (Dupixent®)” NCT07411755 ↗ |
| Known as | DUPIXENT | “This proposal is for a Window of Opportunity (WOO) clinical trial using a novel combination of two Health Canada approved agents, cemiplimab (Libtayo) and dupilumab (Dupixent),...” NCT05967884 ↗22“Dupilumab (DUPIXENT) is indicated for the treatment of children of 6 years and older with moderate-to-sever atopic dermatitis whos disease is not adequately controlled with...” NCT04878770 ↗ “Dupilumab (Dupixent) is a human monoclonal antibody administered via subcutaneous injection to treat various conditions such as Chronic Rhinosinusitis with Nasal Polyps, Asthma...” NCT06461949 ↗ “Dupilumab (Dupixent®), a monoclonal antibody inhibiting the IL-4 and IL-13 pathway by targeting the IL-4-receptor, has been approved for the treatment of moderate-to-severe...” NCT04600362 ↗ “A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects” NCT07334496 ↗ “the effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic inflammation” NCT04943744 ↗ “Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]” NCT04869436 ↗ “Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]” NCT06665971 ↗ “Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]” NCT07358234 ↗ “Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]” NCT04430179 ↗ “U.S. commercial dupilumab (Dupixent®)” NCT07411755 ↗ “dupilumab (also known as Dupixent)” NCT06705387 ↗ “Biological: Dupilumab/Dupixent” NCT03884842 ↗ “Dupixent (dupilumab)” NCT05265234 ↗ “ARM 1 - Dupixent” NCT06226610 ↗ |
| Known as | REGN668 | “Drug: Dupilumab SAR231893 (REGN668)” NCT02898454 ↗6“Dupilumab (SAR231893/REGN668)” NCT03560466 ↗ “Dupilumab SAR231893 (REGN668)” NCT02912468 ↗ “Dupilumab SAR231893 (REGN668)” NCT03620747 ↗ “SAR231893 (REGN668)” NCT01537653 ↗ |
| Known as | Regn668, sar231893 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108675 ↗ |
| Known as | SAR231893 | “Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis” NCT01259323 ↗17“Drug: Dupilumab SAR231893 (REGN668)” NCT02898454 ↗ “Dupilumab SAR231893 (REGN668)” NCT03620747 ↗ “Dupilumab (SAR231893/REGN668)” NCT03560466 ↗ “Dupilumab SAR231893 (REGN668)” NCT02912468 ↗ “Drug: Dupilumab (SAR231893)” NCT05976386 ↗ “Dupilumab (SAR231893)” NCT04823130 ↗ “Dupilumab (SAR231893)” NCT05976360 ↗ “Dupilumab (SAR231893)” NCT05976373 ↗ “Dupilumab SAR231893” NCT04678882 ↗ “Dupilumab SAR231893” NCT04678856 ↗ “Dupilumab SAR231893” NCT04718870 ↗ “Dupilumab SAR231893” NCT04681729 ↗ “Dupilumab SAR231893” NCT04183335 ↗ “Dupilumab SAR231893” NCT04684524 ↗ “Dupilumab SAR231893” NCT03782532 ↗ “Dupilumab SAR231893” NCT05049122 ↗ |
| Known as | SAR231893/REGN668 | “Dupilumab SAR231893/REGN668” NCT02573233 ↗ |
| Action | Inhibit | “indicating blockade of IL-4Rα-mediated signaling” PMID 32348036 ↗ Apr 2020 |
| Modality | Monoclonal antibody | “a fully human monoclonal antibody to the alpha subunit of the interleukin-4 receptor” PMID 23688323 ↗ May 2013 |
| Route | Intravenous | “Intravenously Administered REGN668 in Healthy Volunteers” NCT01015027 ↗ |
| Target | IL4R | “Dupilumab is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors” PMID 32348036 ↗ Apr 2020 |